Sensing the local environment: Actin architecture and Hippo signalling

Current Opinion in Cell Biology

Volumn 31, Issue , 2014, Pages 74-83

  Gaspar, Pedro ^a,b   Tapon, Nicolas ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; F ACTIN; LIM PROTEIN; MEMBRANE PROTEIN; TAZ PROTEIN; UNCLASSIFIED DRUG; YAP PROTEIN; YKI PROTEIN; PROTEIN SERINE THREONINE KINASE;

ACTIN FILAMENT; ACTIN POLYMERIZATION; HIPPO SIGNALLING; MECHANOTRANSDUCTION; MOLECULAR DYNAMICS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; CYTOSKELETON; HOMEOSTASIS; HUMAN; METABOLISM; NEOPLASM; ORGAN SIZE;

ACTINS; ANIMALS; CYTOSKELETON; HOMEOSTASIS; HUMANS; MECHANOTRANSDUCTION, CELLULAR; NEOPLASMS; ORGAN SIZE; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84907556031     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2014.09.003     Document Type: Review

References (105)

1. Winder S.J. Actin-binding proteins. J Cell Sci 2005, 118:651-654.
2. Michelot A., Drubin D.G. Building distinct actin filament networks in a common cytoplasm. Curr Biol 2011, 21:R560-R569.
3. Kustermans G., Piette J., Legrand-Poels S. Actin-targeting natural compounds as tools to study the role of actin cytoskeleton in signal transduction. Biochem Pharmacol 2008, 76:1310-1322.
4. Olson E.N., Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 2010, 11:353-365.
5. Miralles F., Posern G., Zaromytidou A., Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 2003, 113:329-342.
6. Esnault C., Stewart A., Gualdrini F., East P., Horswell S., Matthews N., Treisman R. Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts. Genes Dev 2014, 28:943-958.
7. Lin J.I., Poon C.L.C., Harvey K.F. The Hippo size control pathway-ever expanding. Sci Signal 2013, 6:4.
8. Harvey K.F., Zhang X., Thomas D.M. The Hippo pathway and human cancer. Nat Rev Cancer 2013, 13:246-257.
9. Yu F.X., Guan K.L. The Hippo pathway: regulators and regulations. Genes Dev 2013, 27:355-371.
10. Densham R.M., O'Neill E., Munro J., König I., Anderson K., Kolch W., Olson M.F. MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol 2009, 29:6380-6390.
11. Fernández B.G., Gaspar P., Brás-Pereira C., Jezowska B., Rebelo S.R., Janody F. Actin-capping protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. Development 2011, 138:2337-2346.
12. Jezowska B., Fernández B.G., Amândio A.R., Duarte P., Mendes C., Brás-Pereira C., Janody F. A dual function of Drosophila capping protein on DE-cadherin maintains epithelial integrity and prevents JNK-mediated apoptosis. Dev Biol 2011, 360:143-159.
13. Fernández B.G., Jezowska B., Janody F. Drosophila actin-capping protein limits JNK activation by the Src proto-oncogene. Oncogene 2013, 33:2027-2039.
14. Sansores-Garcia L., Bossuyt W., Wada K.-I., Yonemura S., Tao C., Sasaki H., Halder G. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J 2011, 30:2307-2511.
15. Aragona M., Panciera T., Manfrin A., Giulitti S., Michielin F., Elvassore N., Dupont S., Piccolo S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 2013, 154:1-13.
16. Dupont S., Morsut L., Aragona M., Enzo E., Giulitti S., Cordenonsi M., Zanconato F., Le Digabel J., Forcato M., Bicciato S., et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474:179-183.
17. Wada K.-I., Itoga K., Okano T., Yonemura S., Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138:3907-3914.
18. Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., Xie J., Ikenoue T., Yu J., Li L., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007, 21:2747-2761.
19. Varelas X., Samavarchi-Tehrani P., Narimatsu M., Weiss A., Cockburn K., Larsen B.G., Rossant J., Wrana J.L. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev Cell 2010, 19:831-844.
20. Calvo F., Ege N., Grande-Garcia A., Hooper S., Jenkins R.P., Chaudhry S.I., Harrington K., Williamson P., Moeendarbary E., Charras G., et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013, 15:637-646.
21. Fernandez-Gonzalez R., Zallen J.A. Cell mechanics and feedback regulation of actomyosin networks. Sci Signal 2009, 2:pe78.
22. Feng X., Degese M.S., Iglesias-Bartolome R., Vaque J.P., Molinolo A.A., Rodrigues M., Zaidi M.R., Ksander B.R., Merlino G., Sodhi A., et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry. Cancer Cell 2014, 25:831-845.
23. Zhao B., Li L., Wang L., Wang C.-Y., Yu J., Guan K.-L. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012, 26:54-68.
24. Reginensi A., Scott R.P., Gregorieff A., Bagherie-Lachidan M., Chung C., Lim D.S., Pawson T., Wrana J., McNeill H. Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet 2013, 9:e1003380.
25. Yu F.-X., Zhao B., Panupinthu N., Jewell J.L., Lian I., Wang L.H., Zhao J., Yuan H., Tumaneng K., Li H., et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150:780-791.
26. Zhao B., Li L., Lu Q., Wang L.H., Liu C.-Y., Lei Q., Guan K.-L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011, 25:51-63.
27. Hamaratoglu F., Willecke M., Kango-Singh M., Nolo R., Hyun E., Tao C., Jafar-Nejad H., Halder G. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006, 8:27-36.
28. Zhang N., Bai H., David K.K., Dong J., Zheng Y., Cai J., Giovannini M., Liu P., Anders R.A., Pan D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010, 19:27-38.
29. Bianchi A.B., Hara T., Ramesh V., Gao J., Klein-Szanto A.J., Morin F., Menon A.G., Trofatter J.A., Gusella J.F., Seizinger B.R., et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994, 6:185-192.
30. Hara T., Bianchi A.B., Seizinger B.R., Kley N. Molecular cloning and characterization of alternatively spliced transcripts of the mouse neurofibromatosis 2 gene. Cancer Res 1994, 54:330-335.
31. Bianchi A.B., Mitsunaga S.I., Cheng J.Q., Klein W.M., Jhanwar S.C., Seizinger B., Kley N., Klein-Szanto A.J., Testa J.R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. PNAS 1995, 92:10854-10858.
32. Hirao M., Sato N., Kondo T., Yonemura S., Monden M., Sasaki T., Takai Y., Tsukita S., Tsukita S. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol 1996, 135:37-51.
33. Bretscher A., Reczek D., Berryman M. Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci 1997, 110(Pt 24):3011-3018.
34. Sherman L., Xu H.M., Geist R.T., Saporito-Irwin S., Howells N., Ponta H., Herrlich P., Gutmann D.H. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997, 15:2505-2509.
35. Rong R., Surace E.I., Haipek C.A., Gutmann D.H., Ye K. Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 2004, 23:8447-8454.
36. Surace E.I., Haipek C.A., Gutmann D.H. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 2004, 23:580-587.
37. Okada T., Lopez-Lago M., Giancotti F.G. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 2005, 171:361-371.
38. Sher I., Hanemann C.O., Karplus P.A., Bretscher A. The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Dev Cell 2012, 22:703-705.
39. Jin H., Sperka T., Herrlich P., Morrison H. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 2006, 442:576-579.
40. Serrano I., McDonald P.C., Lock F., Muller W.J., Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun 2013, 4:2976.
41. Yin F., Yu J., Zheng Y., Chen Q., Zhang N., Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013, 154:1342-1355.
42. Li W., You L., Cooper J., Schiavon G., Pepe-Caprio A., Zhou L., Ishii R., Giovannini M., Hanemann C.O., Long S.B., et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010, 140:477-490.
43. Li W., Cooper J., Zhou L., Yang C., Erdjument-Bromage H., Zagzag D., Snuderl M., Ladanyi M., Hanemann C.O., Zhou P., et al. Merlin/NF2 loss-driven tumorigenesis linked to CRL4-mediated inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 2014, 26:48-60.
44. Bossuyt W., Chen C.L., Chen Q., Sudol M., McNeill H., Pan D., Kopp A., Halder G. An evolutionary shift in the regulation of the Hippo pathway between mice and flies. Oncogene 2014, 33:1218-1228.
45. Zhao B., Li L., Lu Q., Wang L.H., Liu C.Y., Lei Q., Guan K.L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011, 25:51-63.
46. Chan S.W., Lim C.J., Chong Y.F., Pobbati A.V., Huang C., Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011, 286:7018-7026.
47. Wang W., Huang J., Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem 2011, 286:4364-4370.
48. Adler J.J., Johnson D.E., Heller B.L., Bringman L.R., Ranahan W.P., Conwell M.D., Sun Y., Hudmon A., Wells C.D. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. PNAS 2013, 110:17368-17373.
49. Paramasivam M., Sarkeshik A., Yates J.R., Fernandes M.J., McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell 2011, 22:3725-3733.
50. Hirate Y., Hirahara S., Inoue K., Suzuki A., Alarcon V.B., Akimoto K., Hirai T., Hara T., Adachi M., Chida K., et al. Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos. Curr Biol 2013, 23:1181-1194.
51. Wells C.D., Fawcett J.P., Traweger A., Yamanaka Y., Goudreault M., Elder K., Kulkarni S., Gish G., Virag C., Lim C., et al. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 2006, 125:535-548.
52. Yi C., Troutman S., Fera D., Stemmer-Rachamimov A., Avila J.L., Christian N., Persson N.L., Shimono A., Speicher D.W., Marmorstein R., et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011, 19:527-540.
53. Yi C., Shen Z., Stemmer-Rachamimov A., Dawany N., Troutman S., Showe L.C., Liu Q., Shimono A., Sudol M., Holmgren L., et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal 2013, 6:ra77.
54. Ling C., Zheng Y., Yin F., Yu J., Huang J., Hong Y., Wu S., Pan D. The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to expanded. PNAS 2010, 107:10532-10537.
55. Badouel C., Gardano L., Amin N., Garg A., Rosenfeld R., Le Bihan T., McNeill H. The FERM-domain protein expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie. Dev Cell 2009, 16:411-420.
56. Oh H., Reddy B.V., Irvine K.D. Phosphorylation-independent repression of Yorkie in Fat-Hippo signaling. Dev Biol 2009, 335:188-197.
57. Lallemand D., Saint-Amaux A.L., Giovannini M. Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells. J Cell Sci 2009, 122:4141-4149.
58. Mana-Capelli S., Paramasivam M., Dutta S., McCollum D. Angiomotins link F-actin architecture to Hippo pathway signaling. Mol Biol Cell 2014, 25:1676-1685.
59. Dai X., She P., Chi F., Feng Y., Liu H., Jin D., Zhao Y., Guo X., Jiang D., Guan K.L., et al. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem 2013, 288:34041-34051.
60. Kadrmas J.L., Beckerle M.C. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 2004, 5:920-931.
61. Golsteyn R.M., Beckerle M.C., Koay T., Friederich E. Structural and functional similarities between the human cytoskeletal protein zyxin and the ActA protein of Listeria monocytogenes. J Cell Sci 1997, 110(Pt 16):1893-1906.
62. Drees B.E., Andrews K.M., Beckerle M.C. Molecular dissection of zyxin function reveals its involvement in cell motility. J Cell Biol 1999, 147:1549-1560.
63. Drees B., Friederich E., Fradelizi J., Louvard D., Beckerle M.C., Golsteyn R.M. Characterization of the interaction between zyxin and members of the Ena/vasodilator-stimulated phosphoprotein family of proteins. J Biol Chem 2000, 275:22503-22511.
64. Fradelizi J., Noireaux V., Plastino J., Menichi B., Louvard D., Sykes C., Golsteyn R.M., Friederich E. ActA and human zyxin harbour Arp2/3-independent actin-polymerization activity. Nat Cell Biol 2001, 3:699-707.
65. Smith M.A., Blankman E., Gardel M.L., Luettjohann L., Waterman C.M., Beckerle M.C. A zyxin-mediated mechanism for actin stress fiber maintenance and repair. Dev Cell 2010, 19:365-376.
66. Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B., Longmore G.D. Ajuba LIM proteins are negative regulators of the Hippo signaling pathway. Curr Biol 2010, 20:657-662.
67. Rauskolb C., Pan G., Reddy B.V.V.G., Oh H., Irvine K.D. Zyxin links fat signaling to the hippo pathway. PLoS Biol 2011, 9:e1000624.
68. Rauskolb C., Sun S., Sun G., Pan Y., Irvine K.D. Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex. Cell 2014, 158:143-156.
69. Yoshigi M., Hoffman L.M., Jensen C.C., Yost H.J., Beckerle M.C. Mechanical force mobilizes zyxin from focal adhesions to actin filaments and regulates cytoskeletal reinforcement. J Cell Biol 2005, 171:209-215.
70. Colombelli J., Besser A., Kress H., Reynaud E.G., Girard P., Caussinus E., Haselmann U., Small J.V., Schwarz U.S., Stelzer E.H.K. Mechanosensing in actin stress fibers revealed by a close correlation between force and protein localization. J Cell Sci 2009, 122:1665-1679.
71. Codelia V.A., Irvine K.D. Hippo signaling goes long range. Cell 2012, 150:669-670.
72. Yonemura S., Wada Y., Watanabe T., Nagafuchi A., Shibata M. alpha-Catenin as a tension transducer that induces adherens junction development. Nat Cell Biol 2010, 12:533-542.
73. Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., Kreger B.T., Vasioukhin V., Avruch J., Brummelkamp T.R., et al. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell 2011, 144:782-795.
74. Kim N.-G., Kim N.-G., Koh E., Koh E., Chen X., Chen X., Gumbiner B.M., Gumbiner B.M. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. PNAS 2011, 108:11930-11935.
75. Lucas E.P., Khanal I., Gaspar P., Fletcher G.C., Polesello C., Tapon N., Thompson B.J. The Hippo pathway polarizes the actin cytoskeleton during collective migration of Drosophila border cells. J Cell Biol 2013, 201:875-885.
76. Hufnagel L., Teleman A.A., Rouault H., Cohen S.M., Shraiman B.I. On the mechanism of wing size determination in fly development. PNAS 2007, 104:3835-3840.
77. Aegerter-Wilmsen T., Aegerter C.M., Hafen E., Basler K. Model for the regulation of size in the wing imaginal disc of Drosophila. Mech Dev 2007, 124:318-326.
78. Aegerter-Wilmsen T., Heimlicher M.B., Smith A.C., de Reuille P.B., Smith R.S., Aegerter C.M., Basler K. Integrating force-sensing and signaling pathways in a model for the regulation of wing imaginal disc size. Development 2012, 139:3221-3231.
79. Mao Y., Tournier A.L., Hoppe A., Kester L., Thompson B.J., Tapon N. Differential proliferation rates generate patterns of mechanical tension that orient tissue growth. EMBO J 2013, 32:2790-2803.
80. Legoff L., Rouault H., Lecuit T. A global pattern of mechanical stress polarizes cell divisions and cell shape in the growing Drosophila wing disc. Development 2013, 140:4051-4059.
81. Nienhaus U., Aegerter-Wilmsen T., Aegerter C.M. Determination of mechanical stress distribution in Drosophila wing discs using photoelasticity. Mech Dev 2009, 126:942-949.
82. Sun Y., Yong K.M., Villa-Diaz L.G., Zhang X., Chen W., Philson R., Weng S., Xu H., Krebsbach P.H., Fu J. Hippo/YAP-mediated rigidity-dependent motor neuron differentiation of human pluripotent stem cells. Nat Mater 2014, 13:599-604.
83. Yang C., Tibbitt M.W., Basta L., Anseth K.S. Mechanical memory and dosing influence stem cell fate. Nat Mater 2014, 13:645-652.
84. Leung C.Y., Zernicka-Goetz M. Angiomotin prevents pluripotent lineage differentiation in mouse embryos via Hippo pathway-dependent and -independent mechanisms. Nat Commun 2013, 4:2251.
85. Cockburn K., Biechele S., Garner J., Rossant J. The hippo pathway member nf2 is required for inner cell mass specification. Curr Biol 2013, 23:1195-1201.
86. Sun G., Irvine K.D. Control of growth during regeneration. Curr Top Dev Biol 2014, 108:95-120.
87. Del Re D.P., Matsuda T., Zhai P., Gao S., Clark G.J., Van Der Weyden L., Sadoshima J. Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J Clin Invest 2010, 120:3555-3567.
88. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer 2009, 9:108-122.
89. Yu F.X., Luo J., Mo J.S., Liu G., Kim Y.C., Meng Z., Zhao L., Peyman G., Ouyang H., Jiang W., et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 2014, 25:822-830.
90. Oh H., Irvine K.D. In vivo regulation of Yorkie phosphorylation and localization. Development 2008, 135:1081-1088.
91. Cho E., Feng Y., Rauskolb C., Maitra S., Fehon R., Irvine K.D. Delineation of a Fat tumor suppressor pathway. Nat Genet 2006, 38:1142-1150.
92. Angus L., Angus L., Moleirinho S., Moleirinho S., Herron L., Herron L., Sinha A., Sinha A., Zhang X., Zhang X., et al. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene 2012, 31:238-250.
93. Moleirinho S., Patrick C., Tilston-Lünel A.M., Higginson J.R., Angus L., Antkowiak M., Barnett S.C., Prystowsky M.B., Reynolds P.A., Gunn-Moore F.J. Willin, an upstream component of the hippo signaling pathway, orchestrates mammalian peripheral nerve fibroblasts. PLOS ONE 2013, 8:e60028.
94. Visser-Grieve S., Hao Y., Yang X. Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway. Oncogene 2012, 31:1189-1195.
95. Genevet A., Wehr M.C., Brain R., Thompson B.J., Tapon N. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell 2010, 18:300-308.
96. Badouel C., Gardano L., Amin N., Garg A., Rosenfeld R., Le Bihan T., Mcneill H. The FERM-domain protein expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie. Dev Cell 2009, 16:411-420.
97. Oh H., Reddy B.V.V.G., Irvine K.D. Phosphorylation-independent repression of Yorkie in Fat-Hippo signaling. Dev Biol 2009, 335:188-197.
98. Yokoyama T., Osada H., Murakami H., Tatematsu Y., Taniguchi T., Kondo Y., Yatabe Y., Hasegawa Y., Shimokata K., Horio Y., et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008, 29:2139-2146.
99. Lavado A., He Y., Paré J., Neale G., Olson E.N., Giovannini M., Cao X. Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development 2013, 140:3323-3334.
100. Külshammer E., Uhlirova M. The actin cross-linker Filamin/Cheerio mediates tumor malignancy downstream of JNK signaling. J Cell Sci 2012, 126:927-938.
101. Silvis M.R., Kreger B.T., Lien W.-H., Klezovitch O., Rudakova G.M., Camargo F.D., Lantz D.M., Seykora J.T., Vasioukhin V. {alpha}-Catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci Signal 2011, 4:ra33.
102. Oka T., Remue E., Meerschaert K., Vanloo B., Boucherie C., Gfeller D., Bader G.D., Sidhu S.S., Vandekerckhove J., Gettemans J., et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J 2010, 432:461-472.
103. Remue E., Meerschaert K., Oka T., Boucherie C., Vandekerckhove J., Sudol M., Gettemans J. TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner. FEBS Lett 2010, 584:4175-4180.
104. Chan S.W., Lim C.J., Huang C., Chong Y.F., Gunaratne H.J., Hogue K.A., Blackstock W.P., Harvey K.F., Hong W. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 2011, 30:600-610.
105. Adler J.J., Heller B.L., Bringman L.R., Ranahan W.P., Cocklin R.R., Goebl M.G., Oh M., Lim H.-S., Ingham R.J., Wells C.D. Amot130 adapts atrophin-1 interacting protein 4 to inhibit Yes-associated protein signaling and cell growth. J Biol Chem 2013, 288:15181-15193.